Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: GBT440 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects

NCT02567682
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 2, 2026, 6:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment

NCT03114540
View directory record Official record
Conditions
Hepatic Impairment
Interventions
GBT440
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 2, 2026, 6:47 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

NCT04218084
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 14 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
Washington D.C., District of Columbia • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 2, 2026, 6:47 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest

NCT02989168
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Hypoxemia
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
45 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • Denver, Colorado • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Sep 2, 2026, 6:47 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease

NCT02850406
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Months to 17 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
13
States / cities
Brentwood, California • Washington D.C., District of Columbia • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 2, 2026, 6:47 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF

NCT02846324
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Hypoxemia
Interventions
GBT440, Placebo
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
45 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 2, 2026, 6:47 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

NCT04724421
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Months to 11 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
33
States / cities
Phoenix, Arizona • San Diego, California • Wilmington, Delaware + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 2, 2026, 6:47 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Effects of Investigational Drug on Oxygenation in Healthy Volunteers Under Hypoxic Conditions

NCT03051711
View directory record Official record
Conditions
Cardio-pulmonary Function
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 2, 2026, 6:47 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)

NCT03036813
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
voxelotor, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 65 Years
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 2, 2026, 6:47 AM EDT
Completed Phase 4 Interventional

Voxelotor Sickle Cell Exercise Study

NCT04581356
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Voxelotor
Drug
Lead sponsor
Elizabeth Yang, MD, PhD
Other
Eligibility
12 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Sep 2, 2026, 6:47 AM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension of Voxelotor

NCT04188509
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Months and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 2, 2026, 6:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose PK Study of GBT440 in Subjects With Renal Impairment

NCT03161015
View directory record Official record
Conditions
Renal Impairment
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Sep 2, 2026, 6:47 AM EDT
Completed Phase 4 Interventional Results available

Actigraphy Improvement With Voxelotor (ActIVe) Study

NCT04400487
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Farmington, Connecticut • Atlanta, Georgia • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Sep 2, 2026, 6:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male Subjects

NCT02497924
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 2, 2026, 6:47 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

NCT03943615
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Birmingham, Alabama • Mobile, Alabama • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 2, 2026, 6:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects

NCT02567695
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 2, 2026, 6:47 AM EDT
Terminated Phase 3 Interventional Results available

Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

NCT03573882
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 65 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
34
States / cities
Little Rock, Arkansas • Oakland, California • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 2, 2026, 6:47 AM EDT